Skip to content

Author

R. Repetti

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

Type II ROS1 Inhibition Overcomes Type I Inhibitor Resistance in ROS1 Fusion-Positive Lung Cancers: A Phase II Trial of Cabozantinib.

BACKGROUND All targeted therapies approved for ROS1-fusion-positive non-small cell lung cancer (NSCLC) are type I inhibitors. These TKIs may induce resistance amenable to type II inhibition. Cabozantinib is a type II ROS1/MET tyrosine kinase inhibitor with preclinical activity against on-target ROS1 resistance mutation...

J. Rubio-Perez, M. Repetto, Ling-Feng Ye et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.